scholarly journals EFFECT OF LDL-C ON RISK OF RECURRENT MYOCARDIAL INFARCTION, UNSTABLE ANGINA, AND ISCHEMIC STROKE IN A HIGH RISK, SECONDARY PREVENTION PATIENT POPULATION

2015 ◽  
Vol 65 (10) ◽  
pp. A53 ◽  
Author(s):  
Ben Taylor ◽  
Ryan Kilpatrick ◽  
Xue Song ◽  
Paul Muntner
Keyword(s):  
Myocardial Infarction ◽  
Ischemic Stroke ◽  
High Risk ◽  
Secondary Prevention ◽  
Unstable Angina ◽  
Patient Population ◽  
Recurrent Myocardial Infarction

Short-term risk stratification using CADILLAC risk score in patients with ST elevation myocardial infarction

2020 ◽  
Vol 41 (Supplement_2) ◽  
Author(s):  
T Satou ◽  
H Kitahara ◽  
K Ishikawa ◽  
T Nakayama ◽  
Y Fujimoto ◽  
...  
Keyword(s):  
Myocardial Infarction ◽  
High Risk ◽  
Adverse Events ◽  
Risk Score ◽  
Risk Group ◽  
Risk Groups ◽  
Low Risk ◽  
Short Term ◽  
Recurrent Myocardial Infarction ◽  
St Elevation

Abstract Background The recent reperfusion therapy for ST-elevation myocardial infarction (STEMI) has made the length of hospital stay shorter without adverse events. CADILLAC risk score is reportedly one of the risk scores predicting the long-term prognosis in STEMI patients. Purpose To invenstigate the usefulness of CADILLAC risk score for predicting short-term outcomes in STEMI patients. Methods Consecutive patients admitted to our university hospital and our medical center with STEMI (excluding shock, arrest case) who underwent primary PCI between January 2012 and April 2018 (n=387) were enrolled in this study. The patients were classified into 3 groups according to the CADILLAC risk score: low risk (n=176), intermediate risk (n=87), and high risk (n=124). Data on adverse events within 30 days after hospitalization, including in-hospital death, sustained ventricular arrhythmia, recurrent myocardial infarction, heart failure requiring intravenous treatment, stroke, or clinical hemorrhage, were collected. Results In the low risk group, adverse events within 30 days were significantly less observed, compared to the intermediate and high risk groups (n=13, 7.4% vs. n=13, 14.9% vs. n=58, 46.8%, p<0.001). In particular, all adverse events occurred within 3 days in the low risk group, although adverse events, such as heart failure (n=4), recurrent myocardial infarction (n=1), stroke (n=1), and gastrointestinal bleeding (n=1), were substantially observed after day 4 of hospitalization in the intermediate and high risk groups. Conclusions In STEMI patients with low CADILLAC risk score, better short-term prognosis was observed compared to the intermediate and high risk groups, and all adverse events occurred within 3 days of hospitalization, suggesting that discharge at day 4 might be safe in this study population. CADILLAC risk score may help stratify patient risk for short-term prognosis and adjust management of STEMI patients. Initial event occurrence timing Funding Acknowledgement Type of funding source: None

Detection of coronary disease patients at high risk for recurrent myocardial infarction by elevated plasma inactive creatine kinase B protein levels

1981 ◽  
Vol 101 (5) ◽  
pp. 561-569 ◽  
Author(s):  
Michael H. Burnam ◽  
Marisa A. Crouch ◽  
Christopher Y.C. Chew ◽  
Winifred Carnegie ◽  
Harvey Hecht ◽  
...  
Keyword(s):  
Myocardial Infarction ◽  
Creatine Kinase ◽  
High Risk ◽  
Coronary Disease ◽  
Elevated Plasma ◽  
Protein Levels ◽  
Recurrent Myocardial Infarction ◽  
Creatine Kinase B

scholarly journals Appropriate secondary prevention and clinical outcomes after acute myocardial infarction according to atherothrombotic risk stratification: The FAST-MI 2010 registry

2018 ◽  
Vol 26 (4) ◽  
pp. 411-419 ◽  
Author(s):  
Victoria Tea ◽  
Marc Bonaca ◽  
Chekrallah Chamandi ◽  
Marie-Christine Iliou ◽  
Thibaut Lhermusier ◽  
...  
Keyword(s):  
Myocardial Infarction ◽  
Acute Myocardial Infarction ◽  
High Risk ◽  
Secondary Prevention ◽  
High Risk Patients ◽  
Risk Patients ◽  
St Elevation ◽  
Group 3 ◽  
Group 2 ◽  
Group 1

Background Full secondary prevention medication regimen is often under-prescribed after acute myocardial infarction. Design The purpose of this study was to analyse the relationship between prescription of appropriate secondary prevention treatment at discharge and long-term clinical outcomes according to risk level defined by the Thrombolysis In Myocardial Infarction (TIMI) Risk Score for Secondary Prevention (TRS-2P) after acute myocardial infarction. Methods We used data from the 2010 French Registry of Acute ST-Elevation or non-ST-elevation Myocardial Infarction (FAST-MI) registry, including 4169 consecutive acute myocardial infarction patients admitted to cardiac intensive care units in France. Level of risk was stratified in three groups using the TRS-2P score: group 1 (low-risk; TRS-2P=0/1); group 2 (intermediate-risk; TRS-2P=2); and group 3 (high-risk; TRS-2P≥3). Appropriate secondary prevention treatment was defined according to the latest guidelines (dual antiplatelet therapy and moderate/high dose statins for all; new-P2Y12 inhibitors, angiotensin-converting-enzyme inhibitor/angiotensin-receptor-blockers and beta-blockers as indicated). Results Prevalence of groups 1, 2 and 3 was 46%, 25% and 29% respectively. Appropriate secondary prevention treatment at discharge was used in 39.5%, 37% and 28% of each group, respectively. After multivariate adjustment, evidence-based treatments at discharge were associated with lower rates of major adverse cardiovascular events (death, re-myocardial infarction or stroke) at five years especially in high-risk patients: hazard ratio = 0.82 (95% confidence interval: 0.59–1.12, p = 0.21) in group 1, 0.74 (0.54–1.01; p = 0.06) in group 2, and 0.64 (0.52–0.79, p < 0.001) in group 3. Conclusions Use of appropriate secondary prevention treatment at discharge was inversely correlated with patient risk. The increased hazard related to lack of prescription of recommended medications was much larger in high-risk patients. Specific efforts should be directed at better prescription of recommended treatment, particularly in high-risk patients.

scholarly journals Influence of Secondary Prevention and Risk Factors to Recurrent Miocard Infark on Acute Coronary Syndrome Patients in General Hospital Surakarta Indonesia

2019 ◽  
Vol 15 (10) ◽  
pp. 136
Author(s):  
Hidayah Karuniawati Karuniawati ◽  
Vionella Moutika Putri ◽  
Tuqa Haitham
Keyword(s):  
Risk Factors ◽  
Myocardial Infarction ◽  
Secondary Prevention ◽  
Statin Therapy ◽  
Antiplatelet Therapy ◽  
Ace Inhibitor ◽  
Chi Square ◽  
Recurrent Myocardial Infarction ◽  
Myocardial Infraction ◽  
Chi Square Test

<p class="0abstract">The patient who had myocardial infraction has a risk of recurrent myocardial infraction. Secondary prevention including antiplatelet, beta-blocker, statin, ACE inhibitor/ARB aims to prevent recurrent myocardial infarction. This study aimed to find the influence of secondary prevention and risk factors on the occurrence of recurrent myocardial infraction. This research was conducted with quantitative and case-control retrospectively. The subjects were 80 respondents consisting of 40 respondents in the case group and 40 respondents in control group patients. Data were analyzed using bivariate analysis of chi-square test followed by multivariate analysis of logistic regression. Rate of recurrent myocardial infarction (MI) with antiplatelet therapy decreased from 64.3% to 34.2%, with beta-blocker therapy decreased from 57.7% to 35.7%, with statin therapy decreased from 65.9% to 30.5%, with ACE inhibitor/ARB therapy decreased from 65.9% to 30.5%, with a combination of fourth therapy reduced from 57.4% to 34.6%. Chi-square test showed that there was a statistically significant relationship between antiplatelet therapy (p = 0.007), statin therapy (p = 0.002), ACE inhibitor / ARB therapy (p = 0.002), family history (p = 0.011) and adherence (p = 0.007) to recurrent MI. While multivariate analysis of logistic regression showed that the variables influencing the incidence of recurrent myocardial infarction were did not use antiplatelet therapy (P = 0,005; OR= 4.006) and statin therapy (P = 0,029; OR= 3.111). The secondary prevention reduced the incident of recurrent myocardial infarction.</p>

Too little aspirin for secondary prevention after acute myocardial infarction in patients at high risk for cardiovascular events: Results from the MITRA study

2004 ◽  
Vol 148 (2) ◽  
pp. 306-311 ◽  
Author(s):  
Birgit Frilling ◽  
Rudolf Schiele ◽  
Anselm Kai Gitt ◽  
Ralf Zahn ◽  
Steffen Schneider ◽  
...  
Keyword(s):  
Myocardial Infarction ◽  
Acute Myocardial Infarction ◽  
High Risk ◽  
Secondary Prevention ◽  
Cardiovascular Events

scholarly journals Correlation between Timi Risk Score and Clinical Outcome in Patients with Unstable Angina Pectoris

2016 ◽  
Vol 17 (2) ◽  
pp. 93-98
Author(s):  
Zorica Savovic ◽  
Violeta Iric-Cupic ◽  
Goran Davidovic
Keyword(s):  
Myocardial Infarction ◽  
High Risk ◽  
Angina Pectoris ◽  
Unstable Angina ◽  
Risk Score ◽  
Risk Group ◽  
Short Term ◽  
Timi Score ◽  
Poor Outcomes ◽  
Timi Risk Score

Abstract Given Taking that the TIMI score is a major predictor of MACE, this study aimed to determine the value of the TIMI risk score in predicting poor outcomes (death, myocardial infarction, recurrent pain) in patients presenting with unstable angina pectoris in short-term observation. A total of 107 patients with APns were examined at the Clinical Centre Kragujevac and were included in the investigation. The TIMI score was determined on the first day of hospitalization. During hospitalization, the following factors were also observed: troponin, ECG evolution, further therapy (pharmacologic therapy and/or emergency PCI or CABG), age, hypertension and hyperlipidaemia. The low-risk group (TIMI 0 - 2) included 30.8% of patients, whereas 47.6% of patients were in the intermediate-risk group (TIMI 3 - 4), and 21.5% of patients were in the high-risk group (TIMI 5 - 7). Good outcomes (without adverse event) and poor outcomes (death, myocardial infarction, and recurring chest pain) were dependent on the TIMI risk score. The increase in TIMI risk score per one unit increased the risk of a poor outcome by 54%. Troponin and TIMI risk score were positively correlated. Our results suggest that the TIMI risk score may be a reliable predictor of a poor outcome (MACE) during the short-term observation of patients with APns. Moreover, patients identified as high-risk benefit from early invasive PCI, enoxaparin and Gp IIb/IIIa inhibitors. Th us, routine use of the TIMI risk score at admission may reduce the number of patients not recognized as high-risk.

Sign in / Sign up

Export Citation Format

Share Document